Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss neighbours and cancer leaders Roche. The deal includes two recently approved GSK products for ...

Pfizer said in October that it is considering ... Walmsley said that “it would be weird” if GSK does not look at buying the business. But GSK is only looking at the business Walmsley said ...

Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...

A HUGE study that has been launched to find treatments for diseases by measuring how the proteins circulating in our bodies ...